Latest News and Press Releases
Want to stay updated on the latest news?
-
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
-
Oslo (Norway), 21 October 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today informed that AstraZeneca has elected not to enter into a definitive agreement for the...
-
Oslo, 06 October 2020 In accordance with the authorisation granted by the Annual General Meeting 27 May 2020, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 540,000 share...
-
Oslo, Norway, 8 September 2020. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 60,500 new shares following...
-
Oslo (Norway), 2 September 2020 – Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the “Company”). 1. ...
-
Oslo (Norway), 1 September 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation and DCprime, the...
-
Oslo (Norway), 26 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year and Q2 2020 results. Please find enclosed the report...
-
Oslo, Norway, 19 August 2020 - PCI Biotech’s (OSE: PCIB) second quarter and first half 2020 interim report will be released on 26 August 2020 at 07.00 CEST. The interim report and presentation will be...
-
Oslo (Norway), 19 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that a case report series from the Phase I study with PCI Biotech's proprietary...
-
Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research...